CLINACIN 150 MG TABLETS FOR DOGS

Country: Ireland

Bahasa: Inggeris

Sumber: HPRA (Health Products Regulatory Authority)

Bahan aktif:

CLINDAMYCIN (AS CLINDAMYCIN HYDROCHLORIDE)

Boleh didapati daripada:

Chanelle Animal Health Ltd.

Kod ATC:

QJ01FF01

INN (Nama Antarabangsa):

CLINDAMYCIN (AS CLINDAMYCIN HYDROCHLORIDE)

Dos:

150 mg/tablet

Borang farmaseutikal:

Tablets

Jenis preskripsi:

POM

Kumpulan terapeutik:

Canine

Kawasan terapeutik:

Clindamycin

Tanda-tanda terapeutik:

Antibacterial

Status kebenaran:

Authorised

Tarikh kebenaran:

1999-11-26

Ciri produk

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clinacin 150mg Tablets for Dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE: Clindamycin 150 mg (as clindamycin hydrochloride)
EXCIPIENT:
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
An oblong white tablet, with a break-line on one side.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of:-
Infected wounds, abscesses and oral cavity/dental infections caused by or associated with clindamycin-sensitive species of;
•
_Staphylococcus _spp.
•
_Streptococcus _spp.
•
_Bacteroides _spp.
•
_Fusobacterium necrophorum_
•
_Clostridium perfringens_
Osteomyelitis
•
_Staphylococcus aureus_
4.3 CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to clindamycin or lincomycin.
Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants because ingestion of clindamycin by these
species may result in severe gastro-intestinal disturbance.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 08/11/2016_
_CRN 7024937_
_page number: 1_
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.
Patients with severe renal and/or hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution
and should be monitored by serum examination during clindamycin therapy.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT